Discounted Cash Flow
Usana Health Sciences Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2017 | $1.0b | $62.5m | $110.6m | 6.0% | $2.57 |
| 2018 | $1.2b (13.6%) | $126.2m (101.8%) | $140.7m (27.2%) | 10.6% (77.7%) | $5.24 (103.9%) |
| 2019 | $1.1b (-10.8%) | $100.5m (-20.4%) | $110.2m (-21.7%) | 9.5% (-10.7%) | $4.44 (-15.3%) |
| 2020 | $1.1b (7.0%) | $124.7m (24.0%) | $145.3m (31.9%) | 11.0% (16.0%) | $5.89 (32.7%) |
| 2021 | $1.1b (0.0%) | $124.7m (0.0%) | $145.3m (0.0%) | 11.0% (0.0%) | $5.89 (0.0%) |
| 2022 | $998.6m (-12.0%) | $116.5m (-6.5%) | $110.8m (-23.7%) | 11.7% (6.2%) | $3.60 (-38.9%) |
| 2023 | $921.0m (-7.8%) | $63.8m (-45.2%) | $56.1m (-49.3%) | 6.9% (-40.6%) | $3.31 (-8.1%) |
| 2024 | $854.5m (-7.2%) | $42.0m (-34.1%) | $50.9m (-9.3%) | 4.9% (-29.0%) | $2.20 (-33.5%) |
| 2025 | $925.3m (8.3%) | $10.8m (-74.4%) | $8.5m (-83.3%) | 1.2% (-76.4%) | $0.58 (-73.6%) |
| 2026 | $925.3m (0.0%) | $10.8m (0.0%) | $8.5m (0.0%) | 1.2% (0.0%) | $0.58 (0.0%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.